Showing 1 - 20 results of 360 for search '"Maria Sklodowska-Curie National Research Institute of Oncology"', query time: 0.37s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center... by Piotr Domański, Mateusz Piętak, Szymon Staneta, Weronika Fortuniak, Barbara Kruczyk, Adam Kobiernik, Piotr Bakuła, Anna Mydlak, Tomasz Demkow, Bożena Sikora-Kupis, Paulina Dumnicka, Jakub Kucharz

    Published 2024-02-01
    “…<i>Materials and Methods:</i> Seventy-one patients with metastatic RCC were treated with second or further lines of cabozantinib at the Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology. Comprehensive data, including demographics, clinicopathological factors, and AEs, were collected from January 2017 to June 2021. …”
    Get full text
    Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    Treatment outcomes of patients with primary tracheal tumors - analysis of a large retrospective series by Aleksandra Piórek, Adam Płużański, Magdalena Knetki-Wróblewska, Kinga Winiarczyk, Sylwia Tabor, Paweł Teterycz, Dariusz M. Kowalski, Maciej Krzakowski

    Published 2024-06-01
    “…Methods We carried out a retrospective analysis of 89 patients with primary tracheal tumors treated at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, over sixteen years. …”
    Get full text
    Article
  14. 14
  15. 15
  16. 16

    Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study by Piotr Domański, Mateusz Piętak, Barbara Kruczyk, Jadwiga Jarosińska, Anna Mydlak, Tomasz Demkow, Marta Darewicz, Bożena Sikora-Kupis, Paulina Dumnicka, Wojciech Kamzol, Jakub Kucharz

    Published 2024-02-01
    “…In this retrospective study, involving seventy-one metastatic RCC (mRCC) patients receiving second or subsequent lines of cabozantinib at the Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, we explored the impact of AEs on overall survival (OS) and progression-free survival (PFS). …”
    Get full text
    Article
  17. 17
  18. 18
  19. 19
  20. 20